Search for a trial

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

The primary objective:To compare LCZ696 to valsartan in reducing the rate of the composite endpoint of cardiovascular death andtotal (first and recurrent) heart failure (HF) hospitalizations, in HF patients (NYHA Class II-IV) with preserved EF (LVEF…

Stem Cell therapy in IschEmic Non-treatable Cardiac disease - SCIENCE

The idea behind this study is to show that stem cell therapy is not just effective and safe but also an accessible, feasible and economically sound therapeutic option for patients with IHD and severe heart failureThe present aim is to perform at…

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes post Worsening Heart Failure

The main objectives of the study are to demonstrate whether sotagliflozin reduces the composite of CV (cardiovascular) death and HHF (hospitalization for heart failure) as compared to placebo in diabetic patients after admission for WHF (worsening…

Fluid REStriction in Heart failure versus liberal fluid UPtake: the FRESH-UP study

To investigate the effect of fluid restriction versus liberal fluid intake on QoL in chronic HF.

Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction.

Primary objectiveTo investigate the effects of semaglutide s.c. 2.4 mg once-weekly on physical function, symptoms and body weight compared with placebo, both added to standard of care, in subjects with obesityrelated HFpEF.Secondary objectivesTo…

Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related
heart failure with preserved ejection fraction, and type 2 diabetes

Primary objectiveTo investigate the effects of semaglutide s.c. 2.4 mg once-weekly on physical function, symptoms and body weight compared with placebo, both added to standard of care, in subjects with obesity-related HFpEF and T2D.Secondary…

Use of mechanical left ventricular unloading in acute decompensated systolic heart failure complicated by cardiogenic shock

To assess the efficacy of early mechanical left ventricular unloading and standard of care (inotropes/vasopressors) versus inotropes/vasopressors alone (standard-of-care) in patients with ADHF and signs of cardiogenic shock.

A Phase 3 Multicenter, Open Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg [or Tafamidis (PF-06291826-00) 61mg] in Subjects Diagnosed with Transthyretin Cardiomyopathy (ATTR-CM))

To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…

Randomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): The CORCINCH-HF
Study

The objective of this study is to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with symptomaticheart failure with reduced ejection fraction (HFrEF).

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant

Primary: • To evaluate whether long-term treatment with bempedoic acid 180 mg/day versus placebo reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease (CVD) who are statin…

Implementation of prehospital high Sensitive troponin and risk Stratification- validation phase

validation Phase objective: Primary objective is to validate the high sensitive Troponin Quidel Triage True hsTnI. Secondary objective is to determine the applicability and repeatability. The focus will be on the ease of use, time spent performing…

Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial (TAVR-UNLOAD)

The purpose of this trial is to determine the safety and efficacy of TAVR via a transfemoral approach in HF patients with moderate AS as compared with OHFT with regard to the composite of death, stroke, hospital admissions, symptoms, functional…

SPIRonolactone In the Treatment of Heart Failure -
A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction

The primary objective of the SPIRIT*HF study is to compare Spironolactone to Placebo in reducing the rate…

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decreased Exercise Tolerance

Primary Objective:* To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) following 20 weeks of treatment with OM or placeboSecondary…

Pacing Away From Heart Failure: Left bundle branch area pacing or biventricular pacing in patients with atrial fibrillation and left ventricular dysfunction

Primary objectives:1. To compare LVESV change between LBBAP and biventricular pacing in patients with AF and LV dysfunction.Secondary objectives: 2. To compare change in quality of life, New York Heart Association functional class, 6-minute walking…